Singapore Exchange Ltd (SGX) is amending its initial public offering (IPO) rules to clarify that life science companies seeking to list on its mainboard exchange do not need to be revenue-generating.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
